Beatris Mastelic-Gavillet
Overview
Explore the profile of Beatris Mastelic-Gavillet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahmed R, Lozano L, Anastasio A, Lofek S, Mastelic-Gavillet B, Rodrigo B, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370724
Benign prostate hyperplasia (BPH) is a frequent condition in aging men, which affects life quality, causing principally lower urinary tract symptoms. Epidemiologic studies suggest that BPH may raise the risk...
2.
Vono M, Mastelic-Gavillet B, Mohr E, Ostensson M, Persson J, Olafsdottir T, et al.
Front Immunol
. 2023 Apr;
14:1155200.
PMID: 37063899
Introduction: C-type lectin receptor (CLR) agonists emerged as superior inducers of primary B cell responses in early life compared with Toll-like receptor (TLR) agonists, while both types of adjuvants are...
3.
Mastelic-Gavillet B, Sarivalasis A, Lozano L, Lofek S, Wyss T, Melero I, et al.
Front Immunol
. 2023 Feb;
14:1119371.
PMID: 36845155
Background: The use of circulating cDC1 to generate anti-cancer vaccines is among the most promising approaches to overcome the limited immunogenicity and clinical efficacy of monocyte-derived DC. However, the recurrent...
4.
Auderset F, Belnoue E, Mastelic-Gavillet B, Lambert P, Siegrist C
Front Immunol
. 2020 Dec;
11:580974.
PMID: 33262759
Novel adjuvants, such as Toll-like receptors (TLRs) agonists, are needed for the development of new formulations able to circumvent limitations of current vaccines. Among TLRs, TLR7/8 agonists represent promising candidates,...
5.
Mastelic-Gavillet B, Sarivalasis A, Lozano L, Wyss T, Inoges S, de Vries I, et al.
Eur J Cancer
. 2020 Jun;
135:173-182.
PMID: 32590296
Background: Dendritic cells (DCs) are the most efficient antigen-presenting cells, hence initiating a potent and cancer-specific immune response. This ability (mainly using monocyte-derived DCs) has been exploited in vaccination strategies...
6.
Ercolano G, Garcia-Garijo A, Salome B, Gomez-Cadena A, Vanoni G, Mastelic-Gavillet B, et al.
Cancer Immunol Res
. 2020 Feb;
8(4):556-564.
PMID: 32019778
Innate lymphoid cells (ILC) are a family of immune cells that are emerging as potent orchestrators of immune responses. In cancer, ILCs display both pro- and antitumorigenic functions depending on...
7.
Mastelic-Gavillet B, Rodrigo B, Decombaz L, Wang H, Ercolano G, Ahmed R, et al.
J Immunother Cancer
. 2019 Oct;
7(1):257.
PMID: 31601268
Background: Several mechanisms are present in the tumor microenvironment (TME) to impair cytotoxic T cell responses potentially able to control tumor growth. Among these, the accumulation of adenosine (Ado) contributes...
8.
Mastelic-Gavillet B, Vono M, Gonzalez-Dias P, Ferreira F, Cardozo L, Lambert P, et al.
Front Immunol
. 2019 Aug;
10:1845.
PMID: 31456798
T follicular helper (T) cells have emerged as a critical limiting factor for controlling the magnitude of neonatal germinal center (GC) reactions and primary vaccine antibody responses. We compared the...
9.
Vono M, Sigrid Eberhardt C, Auderset F, Mastelic-Gavillet B, Lemeille S, Christensen D, et al.
Cell Rep
. 2019 Aug;
28(7):1773-1784.e5.
PMID: 31412246
Maternal antibodies (MatAbs) protect offspring from infections but limit their responses to vaccination. The mechanisms of this inhibition are still debated. Using murine early-life immunization models mimicking the condition prevailing...
10.
Auderset F, Ballester M, Mastelic-Gavillet B, Fontannaz P, Chabaud-Riou M, Reveneau N, et al.
Front Immunol
. 2019 Jul;
10:1520.
PMID: 31333656
Pertussis is still observed in many countries despite of high vaccine coverage. Acellular pertussis (aP) vaccination is widely implemented in many countries as primary series in infants and as boosters...